Johnson & Johnson to Acquire V-Wave for $600 Million Upfront, Targeting Heart Failure Treatment Innovation

Johnson & Johnson (JNJ.US) Agrees to Acquire Medical Device Company V-Wave for $600 Million Upfront. The deal, expected to close by the end of 2024, also includes potential additional regulatory and commercial milestone payments, bringing the total transaction value to approximately $1.1 billion.

It is reported that V-Wave focuses on treatment solutions for cardiovascular diseases. The company's novel implantable device, the Ventura interatrial shunt, aims to treat heart failure. In 2019, the device received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), and in 2020 it obtained the CE Mark (the European Union’s safety certification mark), with the potential to become the first device of its kind to reach the market.

Johnson & Johnson expects the deal to dilute its adjusted earnings by approximately $0.24 per share in 2024 and by about $0.06 per share in 2025.